Inhibikase Therapeutics, Inc.
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | — | — | $18.5K |
| FY2020 | $5.0M | $14.8M | $14.0M |
| FY2021 | $4.1M | $42.5M | $40.8M |
| FY2022 | $3.9M | $24.9M | $7.2M |
| FY2023 | $3.5M | $14.5M | $9.2M |
Assets & Liabilities
| Fiscal Year | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| FY2019 | — | — | $18.5K |
| FY2020 | $5.0M | $14.8M | $14.0M |
| FY2021 | $4.1M | $42.5M | $40.8M |
| FY2022 | $3.9M | $24.9M | $7.2M |
| FY2023 | $3.5M | $14.5M | $9.2M |